Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma

Archives of Pathology and Laboratory Medicine

Volumn 138, Issue 5, 2014, Pages 626-635

  Hwang, David H ^a   Szeto, David P ^a,b   Perry, Anthony S ^a,c   Bruce, Jacqueline L ^a,b   Sholl, Lynette M ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Center for Advanced Molecular Diagnostics   (United States)

^c Banner MD Anderson Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; DNA BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; MUCIN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; RAS PROTEIN; TTF1 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; VERY ELDERLY; WORLD HEALTH ORGANIZATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUCINS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH ORGANIZATION;

EID: 84896685538     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2013-0179-OA     Document Type: Article

References (43)

1. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004: Large Cell Carcinoma. 45-50. World Health Organization Classification of Tumours; vol 10.
2. National Cancer Institute. SEER Cancer Statistics Review 1975-2009. Bethesda, MD: National Cancer Institute; 2011.
3. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244-285.
4. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res. 2012; 18(4):1167-1176.
5. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010; 17(3):889-897.
6. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29(26):3574-3579.
7. Oxnard GR, Binder A, J änne PA. New targetable oncogenes in non-smallcell lung cancer. J Clin Oncol. 2013;31(8):1097-1104.
8. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic nonsmall- cell lung cancer. J Clin Oncol. 2004;22(11):2184-2191. (Pubitemid 41095154)
9. Scagliotti GV, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26(21):3543-3551.
10. NCCN guidelines: non-small cell lung cancer, version 2.2013. Available at: http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf. Accessed March 10, 2013.
11. Hou J, Lambers M, Den Hamer B, et al. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy. J Thorac Oncol. 2012;7(1):105-114.
12. Botling J, Edlund K, Lohr M, et al. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res. 2013;19(1):194-204.
13. Barbareschi M, Cantaloni C, Del Vescovo V, et al. Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis. Am J Clin Pathol. 2011;136(5):773-782.
14. Yamagata N, Shyr Y, Yanagisawa K, et al. A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res. 2003;9(13):4695-4704. (Pubitemid 37323271)
15. Hou J, Aerts J, Den Hamer B, et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One. 2010;5(4): e10312.
16. Takeuchi T, Tomida S, Yatabe Y, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol. 2006; 24(11):1679-1688. (Pubitemid 46622139)
17. Carvalho RH, Haberle V, Hou J, et al. Genome-wide DNA methylation profiling of non-small cell lung carcinomas. Epigenetics Chromatin. 2012;5(1):9.
18. Rekhtman N, Tafe LJ, Chaft JE, et al. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Mod Pathol. 2013;26(4):511-522.
19. Rossi G, Marchioni A, Milani M, et al. TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol. 2004;122(6):884-893. (Pubitemid 39577356)
20. Monica V, Scagliotti GV, Ceppi P, et al. Differential thymidylate synthase expression in different variants of large-cell carcinoma of the lung. Clin Cancer Res. 2009;15(24):7547-7552.
21. Monica V, Ceppi P, Righi L, et al. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol. 2009;22(5):709-717.
22. Au NHC, Cheang M, Huntsman DG, et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol. 2004;204(1):101-109. (Pubitemid 39214487)
23. Conde E, Angulo B, Redondo P, et al. The use of P63 immunohistochemistry for the identification of squamous cell carcinoma of the lung. PLoS One. 2010;5(8):e12209.
24. Pardo J, Martinez-Peñuela AM, Sola JJ, et al. Large cell carcinoma of the lung: an endangered species? Appl Immunohistochem Mol Morphol. 2009;17(5): 383-392.
25. Thunnissen E, Boers E, Heideman DA, et al. Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma. Virchows Arch. 2012;461(6):629-638.
26. Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol. 2010;5(4):442-447.
27. Pelosi G, Rossi G, Bianchi F, et al. Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses. J Thorac Oncol. 2011;6(6):1039-1049.
28. Barletta JA, Yeap BY, Chirieac LR. Prognostic significance of grading in lung adenocarcinoma. Cancer. 2010;116(3):659-669.
29. Buttitta F, Barassi F, Fresu G, et al. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer. 2006;119(11):2586-2591. (Pubitemid 44691311)
30. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer. 2001;92(6):1525-1530. (Pubitemid 32947838)
31. Husgafvel-Pursiainen K, Hackman P, Ridanpää M, et al. K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. Int J Cancer. 1993;53(2):250-256. (Pubitemid 23042874)
32. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990;323(9): 561-565. (Pubitemid 20260082)
33. Mao C, Qiu L-X, Liao R-Y, et al. KRAS mutations and resistance to EGFRTKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer. 2010;69(3):272-278.
34. Rodenhuis S, Van de Wetering ML, Mooi WJ, Evers SG, Van Zandwijk N, Bos JL. Mutational activation of the K-ras oncogene: a possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med. 1987;317(15):929-935. (Pubitemid 17147935)
35. Dogan S, Shen R, Ang DC, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012;18(22):6169-6177.
36. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008;14(18):5731-5734.
37. Riquet M, Foucault C, Berna P, Assouad J, Dujon A, Danel C. Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping. Ann Thorac Surg. 2006;81(6):1988-1995. (Pubitemid 43775587)
38. Barletta JA, Perner S, Iafrate AJ, et al. Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med. 2009;13(8B):1977-1986.
39. Tang X, Kadara H, Behrens C, et al. Abnormalities of the TITF-1 lineagespecific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res. 2011;17(8):2434-2443.
40. Li X, Wan L, Shen H, et al. Thyroid transcription factor-1 amplification and expressions in lung adenocarcinoma tissues and pleural effusions predict patient survival and prognosis. J Thorac Oncol. 2012;7(1):76-84.
41. Solis LM, Behrens C, Raso MG, et al. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer. 2012;118(11):2889-2899.
42. Kadota K, Nitadori J-I, Sarkaria IS, et al. Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma. Cancer. 2013;119(5):931-938.
43. Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology. 2000; 36(1):8-16. (Pubitemid 30055417)